| dc.contributor.author | Tutluoglu, B | |
| dc.contributor.author | Celik, N | |
| dc.contributor.author | Akman, M | |
| dc.contributor.author | Afrasyap, L | |
| dc.contributor.author | Goylusun, V | |
| dc.contributor.author | Yilmaz, T | |
| dc.date.accessioned | 2021-03-04T13:19:33Z | |
| dc.date.available | 2021-03-04T13:19:33Z | |
| dc.date.issued | 1999 | |
| dc.identifier.citation | Yilmaz T., Akman M., Tutluoglu B., Afrasyap L., Goylusun V., Celik N., "Plasma thrombomodulin levels in lung cancer patients", PANMINERVA MEDICA, cilt.41, sa.2, ss.125-128, 1999 | |
| dc.identifier.issn | 0031-0808 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_7bc7d0a9-336a-476c-9212-506450f6c483 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/84707 | |
| dc.description.abstract | Background. Thrombomodulin (TM) is a glycoprotein and besides its anticoagulant property it is accepted as an once developmental antigen. Considering these properties we hypothesised that active TMB might have a role in cancer cell behaviour, | |
| dc.language.iso | eng | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Temel Tıp Bilimleri | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | TIP, GENEL & İÇECEK | |
| dc.title | Plasma thrombomodulin levels in lung cancer patients | |
| dc.type | Makale | |
| dc.relation.journal | PANMINERVA MEDICA | |
| dc.contributor.department | , , | |
| dc.identifier.volume | 41 | |
| dc.identifier.issue | 2 | |
| dc.identifier.startpage | 125 | |
| dc.identifier.endpage | 128 | |
| dc.contributor.firstauthorID | 123341 | |
